Ganirelix
Recommended · restricted Women's healthRestrictedNot applicable line
Prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.
1
Submissions
2009–09
On the record
$15k
ICER range
1 sourced ICER · 2009
ICER stated
Cost basis
Access path
- Nov 2009Recommended · restricted
vs nafarelin
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
Comparative effectiveness
The meta-analysis of analogue stimulation versus non-analogue stimulation found a statistically significant advantage for analogue stimulation in clinical pregnancy rate (RD=7.98%; 95% CI: 3.76%, 12.20%).PSD · Nov 2009
The PBAC considered this advantage for analogue stimulation should be interpreted with caution given that there was a wide range of effect across the trials, with a number of different drugs and doses used and varying patient characteristics. The PBAC noted some studies used human menopausal gonadotropin (hMG), FSH, FSH-hMG as the non-analogue arm while the analogue differed in drug, doses and duration.PSD · Nov 2009
Cost-effectiveness
The base case incremental cost per clinical pregnancy of ganirelix versus nafarelin was estimated to be less than $15,000. The economic evaluation was noted by PBAC as highly uncertain.
The PBAC considered the economic evaluation presented in the submission was highly uncertain. PBAC · 2009
Decision context
PopulationPatients undergoing controlled ovarian stimulation followed by oocyte pick-up and assisted reproductive techniques (IVF/GIFT).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2009 | Recommended · restricted | nafarelin | $15k | RCT |